Bristol-Myers Squibb Company Ce (CELG-RI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bristol-Myers Squibb Company Ce (CELG-RI) Healthcare & Pipeline Overview

Bristol-Myers Squibb Company Ce is a prominent player in the biopharmaceutical sector, specializing in the development of innovative therapies, particularly in oncology and inflammatory diseases, leveraging advanced research and a robust product pipeline to meet critical healthcare needs.

What Is the Investment Thesis for CELG-RI?

Bristol-Myers Squibb Company Ce presents a compelling investment thesis characterized by a strong profit margin of 26.5% and a gross margin of 96.2%, indicating efficient operations and robust pricing power. The company is well-positioned to capitalize on growth catalysts such as the increasing demand for advanced cancer therapies and the expansion of its CAR-T cell therapy portfolio. With a market cap of $245M, Bristol-Myers Squibb has significant room for growth, especially as it continues to innovate and address the evolving healthcare landscape. Ongoing investments in research and development, coupled with strategic partnerships, are expected to enhance its product pipeline and drive revenue growth over the next few years. However, potential risks, including patent expirations and competition from biosimilars, could impact future performance and market share.

Based on FMP financials and quantitative analysis

CELG-RI Key Highlights

Profit margin of 26.5% reflects strong operational efficiency.

• Gross margin of 96.2% indicates robust pricing power and cost management.
• Market cap of $245M highlights the company's current valuation.
• A workforce of 34,100 employees supports extensive R&D and operational capabilities.
• Focus on CAR-T therapies positions the company at the forefront of innovative cancer treatments.

Who Are CELG-RI's Competitors?

CELG-RI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CELG-RI's Key Strengths?

Strong profit and gross margins indicating operational efficiency.

• Established reputation and brand recognition in the biopharmaceutical sector.
• Diverse product portfolio addressing various therapeutic areas.

What Are CELG-RI's Weaknesses?

Market cap of $245M may limit access to capital for expansion.

• Dependence on a few key products for a significant portion of revenue.
• Potential exposure to patent expirations affecting revenue.

What Could Drive CELG-RI Stock Higher?

CELG-RI catalyst: Continued expansion of the CAR-T therapy portfolio with new product launches expected over the next two years.

• Strong demand for innovative cancer therapies driving revenue growth.
• Strategic partnerships enhancing research capabilities and market access.

What Are the Key Risks for CELG-RI?

Financial-distress signal — its Altman Z-Score of 1.41 sits in the distress zone (elevated bankruptcy risk).

• Patent expirations may expose the company to increased competition from generics and biosimilars.
• Regulatory challenges could impact the approval of new therapies.
• Market volatility and economic downturns may affect funding and investment in R&D.

What Are the Growth Opportunities for CELG-RI?

• Growth opportunity 1: Bristol-Myers Squibb's CAR-T cell therapy segment is expected to grow significantly, with the global CAR-T market projected to reach $18 billion by 2027. The company's innovative approach in this area positions it well to capture market share and address critical patient needs in cancer treatment.
• Growth opportunity 2: The expansion of Bristol-Myers Squibb's product pipeline, particularly in immuno-oncology, is anticipated to drive revenue growth. With ongoing clinical trials and a focus on novel therapies, the company aims to introduce several new products over the next five years, potentially increasing its market presence.
• Growth opportunity 3: Strategic partnerships and collaborations with research institutions and other biopharmaceutical companies can enhance Bristol-Myers Squibb's innovation capabilities. By leveraging external expertise and resources, the company can accelerate the development of new therapies and expand its therapeutic offerings.
• Growth opportunity 4: Geographic expansion into emerging markets presents a significant growth avenue for Bristol-Myers Squibb. As healthcare access improves in regions such as Asia-Pacific and Latin America, the demand for innovative biopharmaceutical products is expected to rise, providing opportunities for increased sales.
• Growth opportunity 5: The growing focus on precision medicine and personalized therapies aligns with Bristol-Myers Squibb's research initiatives. By developing targeted treatments based on genetic and molecular profiling, the company can enhance patient outcomes and differentiate itself in a competitive market.

What Threats Does CELG-RI Face?

• Intense competition from established and emerging biopharmaceutical companies.
• Risks associated with regulatory changes impacting product approvals.
• Potential for biosimilar competition affecting market share.

What Are CELG-RI's Competitive Advantages?

• Strong patent portfolio protecting key products and therapies.
• Established brand reputation in the biopharmaceutical industry.
• Robust research and development capabilities leading to innovative therapies.
• Strategic partnerships enhancing market access and product development.

What Does CELG-RI Do?

Bristol-Myers Squibb Company Ce, founded in August 1933, is headquartered in Princeton, New Jersey. The company has a rich history in the biopharmaceutical industry, emphasizing the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Over the decades, it has evolved into a leader in the healthcare sector, focusing on small molecules, biologics, and CAR-T cell therapies. Bristol-Myers Squibb's commitment to addressing unmet medical needs is evident in its extensive research and development efforts aimed at innovative therapies for cancer and inflammatory diseases. The company operates globally, with a diverse product portfolio that includes treatments for various conditions, positioning it competitively against other industry leaders. As of now, Bristol-Myers Squibb employs approximately 34,100 individuals, reflecting its significant scale and operational capacity in the biopharmaceutical market. The company's strategic focus on innovation and patient-centric solutions continues to drive its growth and market relevance.

What Products and Services Does CELG-RI Offer?

• Engage in the discovery and development of biopharmaceutical products.
• Manufacture and market small molecule drugs and biologics.
• Develop innovative CAR-T cell therapies for cancer treatment.
• License and distribute products globally to healthcare providers.
• Conduct extensive research to address unmet medical needs in various therapeutic areas.
• Focus on oncology and inflammatory diseases through targeted therapies.

How Does CELG-RI Make Money?

• Generate revenue through the sale of biopharmaceutical products.
• Leverage research and development investments to create innovative therapies.
• Engage in licensing agreements with other pharmaceutical companies.
• Utilize strategic partnerships to enhance product offerings and market reach.

What Industry Does CELG-RI Operate In?

The biopharmaceutical industry is experiencing significant growth, driven by advancements in technology and an increasing focus on personalized medicine. The global market for biopharmaceuticals is projected to reach over $500 billion by 2026, with a compound annual growth rate (CAGR) of approximately 8%. Bristol-Myers Squibb Company Ce is strategically positioned within this dynamic landscape, competing with major players such as Amgen Inc., Gilead Sciences, Inc., and Pfizer Inc. The company's emphasis on innovative therapies, particularly in oncology, aligns with market trends favoring targeted and effective treatments.

Who Are CELG-RI's Key Customers?

• Healthcare providers including hospitals and clinics.
• Pharmaceutical distributors and wholesalers.
• Patients requiring innovative therapies for cancer and inflammatory diseases.
• Government and private health insurance companies.

How Bristol-Myers Squibb Company Ce Is Valued

Bristol-Myers Squibb Company Ce carries a market capitalization of $245M, placing it in the micro-cap category. Relative to its peer group, CELG-RI's quantitative score of 57/100 is below the peer average of 74/100.

Company Profile

Bristol-Myers Squibb Company Ce operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Christopher S. Boerner. CELG-RI has traded publicly since 2019.

Return on equity for Bristol-Myers Squibb Company Ce stands at 61.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.4%, showing how much profit it generates from its asset base. A current ratio of 2.23 indicates the company holds enough short-term assets to cover its near-term obligations.

Bristol-Myers Squibb Company Ce's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.41 places it in the distress zone, a signal of elevated financial risk.

Bristol-Myers Squibb Company Ce has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 17.3% above estimates on average.

Wall Street analysts project Bristol-Myers Squibb Company Ce revenue of about $49.55B for fiscal 2026, with EPS near $6.93.

CELG-RI Financials

CELG-RI Latest News

CELG-RI Analyst Consensus

CELG-RI MoonshotScore

What Investors Ask About Bristol-Myers Squibb Company Ce (CELG-RI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources